BRAF and colorectal carcinoma: However, whilst PLX8394 was superior to vemurafenib, its unique mode of action did not translate to major differences when compared to another group 1 inhibitor encorafenib, a drug which is approved in combination with cetuximab for the treatment of patients with BRAF mutant CRC [2].